The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationGerm-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Self-citationShah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Self-citationMPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
Self-citationNilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Self-citationJak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81167-8 · Cited by 1,156
Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationEditorial: Some Speculations on the Myeloproliferative Syndromes
DAMESHEK, W. (1951) · Blood · doi:10.1182/blood.v6.4.372.372 · Cited by 1,082
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Self-citationMutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
Macchi, P., Villa, A., Giliani, S., Sacco, M. G., Frattini, A., Porta, F., Ugazio, A. G., Johnston, J. A., Candotti, F., O'Sheai, J. J., et al. (1995) · Nature · doi:10.1038/377065a0 · Cited by 877
Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H. M., Barbui, T., Hanson, C. A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 862
Self-citationWidespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843 · cited 1×
“Although most patients with PV are JAK2V617F positive when assessed using appropriately sensitive allele-specific assays, a small proportion of patients with PV are negative for the JAK2V617F allel”
BackgroundMutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development
Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T.-S., Noguchi, M., Markert, M. L., Buckley, R. H., et al. (1995) · Science · doi:10.1126/science.270.5237.797 · Cited by 803
Bartram, C. R., de Klein, A., Hagemeijer, A., van Agthoven, T., van Kessel, A. G., Bootsma, D., Grosveld, G., Ferguson-Smith, M. A., Davies, T., Stone, M., et al. (1983) · Nature · doi:10.1038/306277a0 · Cited by 747
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Huntly, B. J. P., Shigematsu, H., Deguchi, K., Lee, B. H., Mizuno, S., Duclos, N., Rowan, R., Amaral, S., Curley, D., Williams, I. R., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.015 · Cited by 697
Self-citationCampbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 653
Polycythemia Vera: Stem-Cell and Probable Clonal Origin of the Disease
Adamson, J. W., Fialkow, P. J., Murphy, S., Prchal, J. F., & Steinmann, L. (1976) · New England Journal of Medicine · doi:10.1056/nejm197610212951702 · Cited by 640
Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, E. J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020150 · Cited by 630
Identification of an Acquired JAK2 Mutation in Polycythemia Vera
Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B., & Zhao, Z. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500138200 · Cited by 615
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Longley, B. J., Tyrrell, L., Lu, S.-Z., Ma, Y.-S., Langley, K., Ding, T.-G., Duffy, T., Jacobs, P., Tang, L. H., & Modlin, I. (1996) · Nature Genetics · doi:10.1038/ng0396-312 · Cited by 607
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., et al. (2007) · Nature Genetics · doi:10.1038/ng1926 · Cited by 605
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome
Tartaglia, M., Pennacchio, L. A., Zhao, C., Yadav, K. K., Fodale, V., Sarkozy, A., Pandit, B., Oishi, K., Martinelli, S., Schackwitz, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1939 · Cited by 586
Wernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2005-12-4824 · Cited by 483
Self-citationThrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
Elliott, M. A., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05277.x · Cited by 473
Self-citationSteensma, D. P., Dewald, G. W., Lasho, T. L., Powell, H. L., McClure, R. F., Levine, R. L., Gilliland, D. G., & Tefferi, A. (2005) · Blood · doi:10.1182/blood-2005-03-1183 · Cited by 466
Self-citationLacout, C., Pisani, D. F., Tulliez, M., Gachelin, F. M., Vainchenker, W., & Villeval, J.-L. (2006) · Blood · doi:10.1182/blood-2006-02-002030 · Cited by 435
Bone-Marrow Responses in Polycythemia Vera
(1974) · New England Journal of Medicine · doi:10.1056/nejm197406132902419 · Cited by 420
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G., Marchioli, R., & for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) (2007) · Blood · doi:10.1182/blood-2006-08-042515 · Cited by 416
Nicholson, S. E., Willson, T. A., Farley, A., Starr, R., Zhang, J., Baca, M., Alexander, W. S., Metcalf, D., Hilton, D. J., & Nicola, N. A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.2.375 · Cited by 407
Murphy, S., Peterson, P., Iland, H., & Laszlo, J. (1997) · PubMed · Cited by 404
Levine, R. L. (2005) · Blood · doi:10.1182/blood-2005-05-1898 · Cited by 375
Self-citationDing, J., Komatsu, H., Wakita, A., Kato-Uranishi, M., Ito, M., Satoh, A., Tsuboi, K., Nitta, M., Miyazaki, H., Iida, S., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3471 · Cited by 373
Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J. T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H. M., & Issa, J.-P. J. (2005) · Blood · doi:10.1182/blood-2005-05-1800 · Cited by 369
Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain
Saharinen, P., Takaluoma, K., & Silvennoinen, O. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3387-3395.2000 · Cited by 365
CIS3/SOCS-3 Suppresses Erythropoietin (EPO) Signaling by Binding the EPO Receptor and JAK2
Sasaki, A., Yasukawa, H., Shouda, T., Kitamura, T., Dikic, I., & Yoshimura, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003456200 · Cited by 342
Theocharides, A., Boissinot, M., Girodon, F., Garand, R., Teo, S.-S., Lippert, E., Talmant, P., Tichelli, A., Hermouet, S., & Skoda, R. C. (2007) · Blood · doi:10.1182/blood-2006-12-062125 · Cited by 326
Weniger, M. A., Melzner, I., Menz, C. K., Wegener, S., Bucur, A. J., Dorsch, K., Mattfeldt, T., Barth, T. F. E., & Möller, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209151 · Cited by 322
Carobbio, A., Finazzi, G., Guerini, V., Spinelli, O., Delaini, F., Marchioli, R., Borrelli, G., Rambaldi, A., & Barbui, T. (2007) · Blood · doi:10.1182/blood-2006-09-046342 · Cited by 320
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Walters, D. K., Mercher, T., Gu, T.-L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 317
Self-citationLu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
Self-citationGalm, O., Yoshikawa, H., Esteller, M., Osieka, R., & Herman, J. G. (2003) · Blood · doi:10.1182/blood-2002-06-1735 · Cited by 308
Wolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M., Lee, S. J., Gary Gilliland, D., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05764.x · Cited by 303
Self-citationStat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2
Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J. C., Williams, I. R., Lee, C.-K., Gerthner, R., Kitamura, T., Frantsve, J., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00067-8 · Cited by 303
Self-citationAcquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera
Kralovics, R., Guan, Y., & Prchal, J. T. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00789-5 · Cited by 300
Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404810 · Cited by 298
Self-citationCampbell, P. J., Baxter, E. J., Beer, P. A., Scott, L. M., Bench, A. J., Huntly, B. J. P., Erber, W. N., Kusec, R., Larsen, T. S., Giraudier, S., et al. (2006) · Blood · doi:10.1182/blood-2005-12-013748 · Cited by 298
Scott, L. M., Scott, M. A., Campbell, P. J., & Green, A. R. (2006) · Blood · doi:10.1182/blood-2006-04-018259 · Cited by 294
Jamieson, C. H. M., Gotlib, J., Durocher, J. A., Chao, M. P., Mariappan, M. R., Lay, M., Jones, C., Zehnder, J. L., Lilleberg, S. L., & Weissman, I. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601462103 · Cited by 286
Kralovics, R., Teo, S.-S., Li, S., Theocharides, A., Buser, A. S., Tichelli, A., & Skoda, R. C. (2006) · Blood · doi:10.1182/blood-2005-11-009605 · Cited by 278
Guardiola, P., Anderson, J. E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A. P., Przepiorka, D., O'Donnell, M. R., Polchi, P., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.2831 · Cited by 273
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.
Joos, S., Küpper, M., Ohl, S., von Bonin, F., Mechtersheimer, G., Bentz, M., Marynen, P., Mӧller, P., Pfreundschuh, M. G., Trümper, L. H. P., et al. (2000) · PubMed · Cited by 273
Pardanani, A., Hood, J., Lasho, T., Levine, R. L., Martin, M. B., Noronha, G., Finke, C., Mak, C. C., Mesa, R., Zhu, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404750 · Cited by 272
Self-citationAllogeneic hematopoietic stem cell transplantation for myelofibrosis
Deeg, H. J., Gooley, T. A., Flowers, M. E. D., Sale, G. E., Slattery, J. T., Anasetti, C., Chauncey, T. R., Doney, K., Georges, G. E., Kiem, H., et al. (2003) · Blood · doi:10.1182/blood-2003-06-1856 · Cited by 258
Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.
Gilliland, D. G., Blanchard, K. L., Levy, J., Perrin, S., & Bunn, H. F. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6848 · Cited by 253
Self-citationLevine, R. L., Belisle, C., Wadleigh, M., Zahrieh, D., Lee, S., Chagnon, P., Gilliland, D. G., & Busque, L. (2006) · Blood · doi:10.1182/blood-2005-09-3900 · Cited by 241
Self-citationClinical implications of the JAK2 V617F mutation in essential thrombocythemia
Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Verrucci, M., Ponziani, V, Longo, G., Bosi, A., & Vannucchi, A. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403902 · Cited by 229
Expression of Bcl-x in Erythroid Precursors from Patients with Polycythemia Vera
Silva, M., Richard, C., Benito, A., Sanz, C., Olalla, I., & Fernández-Luna, J. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380902 · Cited by 229
Bellanne-Chantelot, C. (2006) · Blood · doi:10.1182/blood-2005-12-4852 · Cited by 227
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
Campbell, P. J. (2006) · Blood · doi:10.1182/blood-2005-08-3395 · Cited by 224
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Zaleskas, V. M., Krause, D. S., Lazarides, K., Patel, N., Hu, Y., Li, S., & Van Etten, R. A. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000018 · Cited by 220
Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., Curley, D. P., Duclos, N., Rowan, R., Kutok, J. L., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00108-9 · Cited by 216
Self-citationMelzner, I., Bucur, A. J., Brüderlein, S., Dorsch, K., Hasel, C., Barth, T. F. E., Leithäuser, F., & Möller, P. (2005) · Blood · doi:10.1182/blood-2004-09-3701 · Cited by 215
Tefferi, A., Lasho, T. L., Schwager, S. M., Steensma, D. P., Mesa, R. A., Li, C., Wadleigh, M., & Gary Gilliland, D. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05776.x · Cited by 207
Self-citationRondelli, D., Barosi, G., Bacigalupo, A., Prchal, J. T., Popat, U., Alessandrino, E. P., Spivak, J. L., Smith, B. D., Klingemann, H. G., Fruchtman, S., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4299 · Cited by 199
Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease
Bumm, T. G. P., Elsea, C., Corbin, A. S., Loriaux, M., Sherbenou, D., Wood, L., Deininger, J., Silver, R. T., Druker, B. J., & Deininger, M. W. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2210 · Cited by 198
Falanga, A., Marchetti, M., Vignoli, A., Balducci, D., Russo, L., Guerini, V., & Barbui, T. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.01.053 · Cited by 194
Lindauer, K., Loerting, T., Liedl, K. R., & Kroemer, R. T. (2001) · Protein Engineering, Design and Selection · doi:10.1093/protein/14.1.27 · Cited by 182
Delhommeau, F., Dupont, S., Tonetti, C., Massé, A., Godin, I., Couedic, J.-P. L., Debili, N., Saulnier, P., Casadevall, N., Vainchenker, W., et al. (2007) · Blood · doi:10.1182/blood-2006-03-007146 · Cited by 178
Frantsve, J., Schwaller, J., Sternberg, D. W., Kutok, J., & Gilliland, D. G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.10.3547-3557.2001 · Cited by 171
Self-citationJak family of kinases in cancer
Verma, A., Kambhampati, S., Parmar, S., & Platanias, L. C. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023805715476 · Cited by 161
Scott, L. M., Campbell, P. J., Baxter, E. J., Todd, T., Stephens, P., Edkins, S., Wooster, R., Stratton, M. R., Futreal, P. A., & Green, A. R. (2005) · Blood · doi:10.1182/blood-2005-05-2087 · Cited by 158
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
Ishii, T., Bruno, E., Hoffman, R., & Xu, M. (2006) · Blood · doi:10.1182/blood-2006-04-017392 · Cited by 148
Jak2: normal function and role in hematopoietic disorders
Ihle, J. N., & Gilliland, D. G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.009 · Cited by 143
Self-citationThe inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Trudel, S., Stewart, A. K., Rom, E., Wei, E. N., Li, Z. H., Kotzer, S., Chumakov, I., Singer, Y., Chang, H., Liang, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4179 · Cited by 143
Finazzi, G., Rambaldi, A., Guerini, V., et al. (2007) · Haematologica · doi:10.3324/haematol.10634 · Cited by 142
Hookham, M. B., Elliott, J., Suessmuth, Y., Staerk, J., Ward, A. C., Vainchenker, W., Percy, M. J., McMullin, M. F., Constantinescu, S. N., & Johnston, J. A. (2007) · Blood · doi:10.1182/blood-2006-08-039735 · Cited by 135
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
Jones, A., Silver, R., Waghorn, K., Curtis, C., Kreil, S., Zoi, K., Hochhaus, A., Oscier, D., Metzgeroth, G., Lengfelder, E., et al. (2005) · Blood · doi:10.1182/blood-2005-09-3917 · Cited by 132
Malinge, S., Abdelali, R. B., Settegrana, C., Radford‐Weiss, I., Debré, M., Beldjord, K., Macintyre, E. A., Villeval, J., Vainchenker, W., Berger, R., et al. (2006) · Blood · doi:10.1182/blood-2006-09-045963 · Cited by 126
Tefferi, A., Lasho, T. L., Mesa, R. A., Pardanani, A. D., Ketterling, R. P., & Hanson, C. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404711 · Cited by 124
Self-citationMercher, T., Wernig, G., Moore, S. A., Levine, R. L., Gu, T.-L., Fröhling, S., Cullen, D., Polakiewicz, R. D., Bernard, O., Boggon, T. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-014712 · Cited by 116
Self-citationGarçon, L., Rivat, C., James, C., Lacout, C., Camara‐Clayette, V., Ugo, V., Lécluse, Y., Griscelli, A. B., & Vainchenker, W. (2006) · Blood · doi:10.1182/blood-2005-10-009514 · Cited by 107
STAT3 is constitutively active in some patients with Polycythemia rubra vera
Röder, S., Steimle, C., Meinhardt, G., & Pahl, H. L. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00637-3 · Cited by 93
Familial Erythrocytosis Associated With a Short Deletion in the Erythropoietin Receptor Gene
Arcasoy, M. O., Degar, B. A., Harris, K. W., & Forget, B. G. (1997) · Blood · doi:10.1182/blood.v89.12.4628 · Cited by 82
Melzner, I., Weniger, M. A., Bucur, A. J., Brüderlein, S., Dorsch, K., Hasel, C., Leithäuser, F., Ritz, O., Dyer, M. J. S., Barth, T. F. E., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21485 · Cited by 70
Tefferi, A., Huang, J., Schwager, S. M., Li, C., Wu, W., Pardanani, A. D., & Mesa, R. A. (2007) · Cancer · doi:10.1002/cncr.22630 · Cited by 67
Self-citationLessons From Familial Myeloproliferative Disorders
Skoda, R. C., & Prchal, J. T. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.08.002 · Cited by 49
Tefferi, A., & Pardanani, A. D. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.5.599 · Cited by 33
Self-citationDobrzański, P., Hexner, E. O., Serdikoff, C., Jan, M., Swider, C. R., Robinson, C., Yang, S. Q., Angeles, T. S., Emerson, S. G., Carroll, M. P., et al. (2006) · Blood · doi:10.1182/blood.v108.11.3594.3594 · Cited by 21
Cited by
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Martinez, J., Malireddi, R. K. S., Lu, Q., Cunha, L. D., Pelletier, S., Gingras, S., Orchard, R., Guan, J.-L., Tan, H., Peng, J., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3192 · Cited by 758
RetractedModulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Li, X., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 645
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., & Kouzarides, T. (2009) · Nature · doi:10.1038/nature08448 · Cited by 622
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811761106 · Cited by 562
Metadata
- Authors
- Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G.
- Venue
- Nature Reviews Cancer
- Published
- 2007-09
- Volume
- 7
- Issue
- 9
- Pages
- 673-683
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2054753195
- Cited by
- 588
- References
- 101
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.